 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Efficacy and safety of phase 3 nivolumab vs gemcitabine or adriamycin for platinum-resistant ovarian cancer

J Clin Oncol: Efficacy and safety of phase 3 nivolumab vs gemcitabine or adriamycin for platinum-resistant ovarian cancer

 Last Update: 2021-09-11
 Source: Internet
 Author: User

Tags

different study designs

prevacid 15 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Ovarian cancer is the eighth most common cancer among women in the world, with high morbidity and mortality

Ovarian cancer

A multicenter, randomized phase 3 study with a development label evaluated nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal adriamycin [PLD]) for platinum-resistant ovarian cancer Efficacy and safety

Recruited patients with platinum-resistant epithelial ovarian cancer who received ≤1 regimen treatment and ECOG performance score ≤1 after clear platinum resistance, were randomly divided into two groups at 1:1, and received nivolumab (240 mg, 1 time/2 weeks, that is, a course of treatment) or chemotherapy (GEM: 1000 mg/m2, input within 30 minutes, repeated administration on 1/8/15 days, 28 days as a course of treatment; or PLD: 50 mg/m2, 1 Times/4 weeks, that is, one course of treatment)

OS and PFS of two groups of patients

From October 2015 to December 2017, a total of 316 patients were randomly assigned to the nivolumab group (157) or the GEM/PLD group (159)

Wu satisfied monoclonal antibody group and median OS GEM / PLD group was 10.

Remission rate and duration of remission in the two groups

The overall response rate between the two groups was not statistically different (7.

There was no statistical difference in the total response rate between the two groups.

Although well tolerated, compared with gemcitabine or pegylated liposomal adriamycin, nivolumab did not improve the overall survival of platinum-resistant ovarian cancer patients, and the progression-free survival did not improve shorter overall survival, although well tolerated, but compared with gemcitabine or pegylated liposomal doxorubicin, satisfied that Wu did not improve mAb platinum-resistant ovarian cancer patients, and progression-free survival It's shorter

Supplement: Some readers have noticed that the median duration of remission in the nivolumab group was significantly longer than that in the GEM/PLD group (18.

Original source:

Junzo Hamanishi, et al.

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.